InfraScan gains FDA backing for next-gen brain hematoma detector

InfraScan won FDA approval for a next-generation handheld device designed to detect brain hematomas, a little more than a year after becoming one of the first to gain U.S. regulators' blessing for such a device. The company's latest device iteration--known as the Infrascanner Model 2000--uses near-infrared tech to spot intracranial bleeding. This is important, InfraScan explains, because the device can quickly identify patients that could gain from an immediate CT scan or neurosurgery. The U.S. Navy and Marine Corps helped develop the device. MedLogic will be selling the device to U.S. civilian customers; ADS Medical is the distributor for the U.S. military market. Release

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.